fda approves bayer's nubeqa (darolutamide) for non-metastatic castration-resistant prostate cancer
Published 5 years ago • 2K plays • Length 1:36Download video MP4
Download video MP3
Similar videos
-
11:35
nubeqa - a treatment for non-metastatic castration-resistant prostate cancer
-
5:01
fda d.i.s.c.o.: a new drug approval for non-metastatic castration-resistant prostate cancer
-
8:37
nubeqa treatment option for non-metastatic castration-resistant prostate cancer
-
2:28
usfda approves doralutamide nubeqa for prostate cancer
-
12:08
new fda approval: darolutamide for hormone-sensitive disease | mark scholz, md | pcri
-
3:50
darolutamide (nubeqa) lupron for high risk prostate cancer | learn about clinical trials
-
2:29
update: fda approves apalutamide (erleada) for metastatic castration-sensitive prostate cancer
-
1:35
darolutamide and survival in nonmetastatic, castration-resistant prostate cancer
-
2:21
u.s. fda approves addition of overall survival and other secondary endpoint data to nubeqa
-
3:57
nubeqa (darolutamide), a hormone therapy | ask a prostate expert, mark scholz, md
-
0:20
darolutamide - nubeqa in a nutshell.
-
6:46
what is nubeqa for prostate cancer and how does it work? | ask a prostate expert, mark scholz, md
-
14:39
new fda approved parp inhibitor: talzenna (talazoparib) & xtandi | #markscholzmd #alexscholz #pcri
-
5:12
darolutamide for nmcrpc: results of the aramis trial
-
7:50
darolutamide(nubeqa) for non metastatic castration resistant prostate cancer
-
2:40
dr. posadas discusses darolutamide in castration-resistant prostate cancer
-
2:38
safety outcomes of darolutamide vs apalutamide and enzalutamide in nmcrpc
-
9:36
new prescribing information on survival benefit for nubeqa® (darolutamide) approved
-
4:49
darolutamide (nubeqa) a newly fda-approved drug explained in detail by dr. pramil cheriyath md